AR103027A2 - Una composición del factor vii (fvii) transgénico, un proceso para prepararla, y una composición farmacéutica - Google Patents

Una composición del factor vii (fvii) transgénico, un proceso para prepararla, y una composición farmacéutica

Info

Publication number
AR103027A2
AR103027A2 ARP150104084A ARP150104084A AR103027A2 AR 103027 A2 AR103027 A2 AR 103027A2 AR P150104084 A ARP150104084 A AR P150104084A AR P150104084 A ARP150104084 A AR P150104084A AR 103027 A2 AR103027 A2 AR 103027A2
Authority
AR
Argentina
Prior art keywords
composition
factor vii
transgenic
fvii
glucan forms
Prior art date
Application number
ARP150104084A
Other languages
English (en)
Inventor
Bihoreau Nicolas
Nony Emmanuel
Sami Chtourou Abdessatar
Original Assignee
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37903443&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR103027(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lfb Biotechnologies filed Critical Lfb Biotechnologies
Publication of AR103027A2 publication Critical patent/AR103027A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se refiere a una composición del Factor VII transgénico, en la que cada molécula de Factor VII de la composición contiene formas de glucano unidas a sitios de N-glucosilación, donde entre todas las moléculas de Factor II de dicha composición, prevalecen las formas de glucano biantenarias, bisialiladas y no fucosiladas. También se refiere a dicha composición para ser empleada como un medicamento, así como también, a un proceso que permite preparar, entre otras cosas, dicha composición. Reivindicación 1: Una composición del Factor VII (FVII) transgénico, en la que cada molécula de Factor VII de la composición contiene formas de glucano unidas a sitios de N-glucosilación: donde entre todas las moléculas del Factor VII de dicha composición la proporción de formas de glucano biantenarias, bisialiladas y no fucosiladas es superior o igual al 45%, y donde todos los ácidos siálicos del Factor VII de dicha composición presentan uniones a2-6, y donde la molécula de Factor VII ha sido expresada en las glándulas mamarias de un mamífero transgénico no humano. Reivindicación 6: Una composición farmacéutica que comprende Factor VII de acuerdo con una cualquiera de las reivindicaciones 1 a 4 como un componente activo, para el tratamiento de traumatismos hemorrágicos múltiples.
ARP150104084A 2006-08-01 2015-12-15 Una composición del factor vii (fvii) transgénico, un proceso para prepararla, y una composición farmacéutica AR103027A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0607016A FR2904558B1 (fr) 2006-08-01 2006-08-01 "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"

Publications (1)

Publication Number Publication Date
AR103027A2 true AR103027A2 (es) 2017-04-12

Family

ID=37903443

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070103379A AR062162A1 (es) 2006-08-01 2007-08-01 Una composicion del factor vii recombinante o transgenico que exhibe principalmente formas de glicano no fucosilado bisialilado y biantenario
ARP150104084A AR103027A2 (es) 2006-08-01 2015-12-15 Una composición del factor vii (fvii) transgénico, un proceso para prepararla, y una composición farmacéutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP070103379A AR062162A1 (es) 2006-08-01 2007-08-01 Una composicion del factor vii recombinante o transgenico que exhibe principalmente formas de glicano no fucosilado bisialilado y biantenario

Country Status (13)

Country Link
US (2) US20090239788A1 (es)
EP (1) EP2049150A2 (es)
JP (2) JP5653619B2 (es)
KR (1) KR101233630B1 (es)
CN (2) CN103397011B (es)
AR (2) AR062162A1 (es)
AU (1) AU2007280330B2 (es)
BR (1) BRPI0715420A2 (es)
CA (2) CA2876621A1 (es)
FR (1) FR2904558B1 (es)
IL (1) IL196379A (es)
TW (1) TWI391400B (es)
WO (1) WO2008015339A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275432A1 (en) 2003-12-01 2011-01-19 Novo Nordisk Health Care AG Nanofiltration of factor VII solutions to remove virus
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
WO2009118460A1 (fr) * 2008-03-25 2009-10-01 Bioprotein Technologies Sa Lapins transgeniques producteurs de facteur vii humain
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
WO2013017555A1 (en) 2011-08-01 2013-02-07 Lfb-Biotechnologies Factor vii compositions with specific glycosylation for controlled half-life
EP2554161A1 (en) 2011-08-02 2013-02-06 LFB Biotechnologies Pharmaceutical composition comprising factor VII encapsulated in micelles
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
MX2015010427A (es) 2013-02-13 2016-03-17 Lab Francais Du Fractionnement Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos.
EP2956003A2 (en) * 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
WO2016089919A1 (en) 2014-12-01 2016-06-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229342A (en) * 1977-05-18 1980-10-21 Rhone-Poulenc Industries Process for extracting proteins from milk using silica and anion exchange resins
NL8204923A (nl) * 1982-12-21 1984-07-16 Stichting Nl I Zuivelonderzoek Werkwijze voor het bereiden van een precipitaat van caseine en wei-eiwit alsmede aldus bereid precipitaat.
DE122007000007I2 (de) * 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
FR2632524B1 (fr) * 1988-06-09 1992-03-13 Fondation Nale Transfusion San Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament
DE4028800A1 (de) * 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
US6984772B1 (en) * 1994-02-18 2006-01-10 Virginia Tech Intellectual Properties, Inc. Transgenic non-human mammals producing fibrinogen in their milk
FR2684999A1 (fr) * 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9408717D0 (en) * 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US5880327A (en) * 1994-09-21 1999-03-09 American National Red Cross Transgenic mammals expressing human coagulation factor VIII
IL130964A0 (en) * 1997-01-16 2001-01-28 Cytel Corp Practical in vitro sialylation of recombinant glycoproteins
US5880237A (en) * 1997-01-31 1999-03-09 Nalco Chemical Company Preparation and utility of water-soluble polymers having pendant derivatized amide, ester or ether functionalities as ceramics dispersants and binders
US6238894B1 (en) * 1998-11-04 2001-05-29 Diane Taylor α1,2 fucosyltransferase
US6183803B1 (en) * 1999-06-11 2001-02-06 Biosante Pharmaceuticals, Inc. Method for processing milk
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
RU2278123C2 (ru) * 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
US6903069B2 (en) * 2000-10-02 2005-06-07 Novo Nordisk Health Care A/S Factor VII glycoforms
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
AU2003240439B2 (en) * 2002-06-21 2009-05-21 Novo Nordisk Health Care Ag Pegylated factor VII glycoforms
FR2841747B1 (fr) * 2002-07-02 2004-08-20 Cie Laitiere Europeenne Isolat de proteines de lait et procede pour sa preparation
WO2005024006A2 (en) * 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
WO2006004675A2 (en) * 2004-06-25 2006-01-12 Altor Bioscience Corporation Production of tissue factor in plants

Also Published As

Publication number Publication date
WO2008015339A2 (fr) 2008-02-07
CA2658800C (en) 2015-03-31
FR2904558B1 (fr) 2008-10-17
EP2049150A2 (fr) 2009-04-22
KR20090040892A (ko) 2009-04-27
AR062162A1 (es) 2008-10-22
CN101495133A (zh) 2009-07-29
CA2876621A1 (en) 2008-02-07
TWI391400B (zh) 2013-04-01
US20090239788A1 (en) 2009-09-24
AU2007280330A1 (en) 2008-02-07
JP2015042678A (ja) 2015-03-05
JP5653619B2 (ja) 2015-01-14
KR101233630B1 (ko) 2013-02-18
CA2658800A1 (en) 2008-02-07
TW200825102A (en) 2008-06-16
CN103397011B (zh) 2016-10-05
JP2009545575A (ja) 2009-12-24
CN103397011A (zh) 2013-11-20
US20130189244A1 (en) 2013-07-25
WO2008015339A3 (fr) 2008-04-17
IL196379A0 (en) 2011-08-01
FR2904558A1 (fr) 2008-02-08
AU2007280330B2 (en) 2011-11-10
IL196379A (en) 2016-04-21
BRPI0715420A2 (pt) 2013-07-02

Similar Documents

Publication Publication Date Title
AR103027A2 (es) Una composición del factor vii (fvii) transgénico, un proceso para prepararla, y una composición farmacéutica
UY38258A (es) Moléculas que tienen utilidad plaguicida, y composiciones y procesos, relacionados con ellas
AR061430A1 (es) Una composicion de factor vii recombinante o transgenico, exhibiendo cada molecula del factor vii dos sitios de n-glicosilacion con partes de glicano definidas
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
UY30098A1 (es) Compuestos de tiazol y metodos de uso
AR066130A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
NI200800020A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización.
BR112014005358A2 (pt) composição para alívio da dor, compreendendo um agonista seletivo de trpv1, e a sua fabricação e utilização
BRPI0810431A8 (pt) Processo para utilização aperfeiçoada do potencial de produção de plantas transgênicas
UY31198A1 (es) Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones.
AR053302A1 (es) Acidos heterociclilaceticos como inhibidores de tafia, proceso para su preparacion y su uso para la preparacion de un medicamento
CL2008003674A1 (es) Composicion farmaceutica como tableta de rapida desintegracion oral que contiene difenhidramina recubiertas con un recubrimiento enmascarador de sabor y granulos de dispersion rapida que comprenden un desintegrador, un alcohol de azucar y/o un sacarido; metodo para preparla, util para afecciones respiratorias, entre otras.
CR10056A (es) [(1h-indol-5-il)-heteroariloxi]-(1-aza-biciclo[3.3.1]nonanos como ligandos colinérgicos del n-achr para el tratamiento de trastornos piscóticos y neurodegenerativos
BR112014031788A2 (pt) composições e métodos para o tratamento de diabetes
CU20130063A7 (es) Proceso de producción de depsipéptidos cíclicos
BR112014019622B8 (pt) composto, seus usos, composição pesticida, material de propagação de plantas tratado e composições farmacêuticas
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
UY31780A (es) Fenoxibenzamidas sustituidas
CO6331434A2 (es) Nuevos compuestos
UY30501A1 (es) Neurotrofinas modificadas post-trasduccionalmente
RU2009116832A (ru) Композиция, включающая арбидол в составе фосфолипидных наночастиц
CL2009000637A1 (es) Compuestos derivados sulfonamida sustituido, antagonista b1r; composición farmacéutica que los comprende; proceso de preparación de los compuestos, y uso en el tratamiento del dolor causado por inflamación, dolor agudo, neuropático, visceral, también en diabetes, migraña, entre otras.
CO2023005057A2 (es) Compuestos y composiciones como moduladores de señalización tlr
GT200600421A (es) Formas cristalinas polimórficas de la sal de di-sodio del ácido n-(5-clorosaliciloil)-8-aminocaprilico

Legal Events

Date Code Title Description
FB Suspension of granting procedure